Literature DB >> 22736042

Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients.

Wei Jiang1, Lei Li, Yuan Tang, Wen-yan Zhang, Wei-ping Liu, Gan-di Li.   

Abstract

The forkhead box protein P1 (FOXP1) expression resulted from chromosome translocation was found in MALT lymphoma, and its nuclear expression in diffuse large B cell lymphoma has been believed to be a poor prognostic factor. In our study, FOXP1 expression was investigated in its relationship to the occurrence of large tumor cells, clinical features, and prognosis in a series of 115 MALT lymphomas divided into two groups with or without the large tumor cells. All cases were morphologically reviewed, and FOXP1 expression was detected both in mRNA and protein levels by real-time PCR, immunochemical staining, and Western blot hybridization. All available clinical data were collected. In the MALT lymphoma with large cells, FOXP1 expression was higher at both mRNA (P = 0.008) and protein (P = 0.000) levels than that in group without large cells, and most large tumor cells showed FOXP1 positivity. It was also found that cases beyond Ann Arbor stage I have a higher FOXP1 expression rate than cases in stage I (P = 0.01), moreover, FOXP1-positive group has more plasmacytic differentiation (P = 0.025), deeper filtrating depth in digestive tract (P = 0.039), and a higher Ki67 proliferation index (P = 0.022). However, no statistical significance was identified in the involved anatomic sites and prognosis. Our data demonstrated the close relationship between FOXP1 nuclear expression and the occurrence of large tumor cells in MALT lymphoma, which suggested the possibility of large cell transformation of FOXP1-positive cases. And FOXP1 positivity was associated with enhanced invasion and proliferation ability of tumor cells. In the thyroid cases, the FOXP1 positivity showed a poorer prognosis (P = 0.043), but the significance was not found in the overall survival analysis (P = 0.1123).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736042     DOI: 10.1007/s12032-012-0288-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

1.  FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.

Authors:  Sylvia Hoeller; Aurelia Schneider; Eugenia Haralambieva; Stephan Dirnhofer; Alexandar Tzankov
Journal:  Histopathology       Date:  2010-06-23       Impact factor: 5.087

Review 2.  Forkhead transcription factors: key players in development and metabolism.

Authors:  Peter Carlsson; Margit Mahlapuu
Journal:  Dev Biol       Date:  2002-10-01       Impact factor: 3.582

3.  The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.

Authors:  A H Banham; N Beasley; E Campo; P L Fernandez; C Fidler; K Gatter; M Jones; D Y Mason; J E Prime; P Trougouboff; K Wood; J L Cordell
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

4.  The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo.

Authors:  D Weigel; G Jürgens; F Küttner; E Seifert; H Jäckle
Journal:  Cell       Date:  1989-05-19       Impact factor: 41.582

5.  The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type.

Authors:  G Ott; T Katzenberger; A Greiner; J Kalla; A Rosenwald; U Heinrich; M M Ott; H K Müller-Hermelink
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

6.  BCL10 gene mutation in lymphoma.

Authors:  M Q Du; H Peng; H Liu; R A Hamoudi; T C Diss; T G Willis; H Ye; A Dogan; A C Wotherspoon; M J Dyer; P G Isaacson
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

7.  T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.

Authors:  B Streubel; U Vinatzer; A Lamprecht; M Raderer; A Chott
Journal:  Leukemia       Date:  2005-04       Impact factor: 11.528

8.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Authors:  William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  [Clonal relationship between transformed and non-transformed components in mucosa-associated lymphoid tissue lymphoma].

Authors:  Wei Jiang; Gan-di Li; Lei Li; Yuan Tang; Yan-mei He
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2007-11
View more
  5 in total

1.  C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.

Authors:  Wenting Huang; Lei Guo; Hongyan Liu; Bo Zheng; Jianming Ying; Ning Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 2.  The emerging role of transcription factor FOXP3 in thyroid cancer.

Authors:  Zhongqin Gong; Hao Jia; Lingbin Xue; Dongcai Li; Xianhai Zeng; Minghui Wei; Zhimin Liu; Michael C F Tong; George G Chen
Journal:  Rev Endocr Metab Disord       Date:  2021-08-31       Impact factor: 6.514

3.  Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1.

Authors:  Leila Rouhigharabaei; Julio Finalet Ferreiro; Thomas Tousseyn; Jo-Anne van der Krogt; Natalie Put; Eugenia Haralambieva; Carlos Graux; Brigitte Maes; Carmen Vicente; Peter Vandenberghe; Jan Cools; Iwona Wlodarska
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

4.  FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.

Authors:  Eun Jung Choi; Eun Jin Seo; Dae Kyoung Kim; Su In Lee; Yang Woo Kwon; Il Ho Jang; Ki-Hyung Kim; Dong-Soo Suh; Jae Ho Kim
Journal:  Oncotarget       Date:  2016-01-19

Review 5.  Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis.

Authors:  Jian Xiao; Bixiu He; Yong Zou; Xi Chen; Xiaoxiao Lu; Mingxuan Xie; Wei Li; Shuya He; Shaojin You; Qiong Chen
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.